Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03829410
Title Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Trovagene, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Mayo Clinic Cancer Center Phoenix Arizona 85054 United States Details
CARTI Cancer Center Little Rock Arkansas 72205 United States Details
USC Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
Mayo Clinic Florida Jacksonville Florida 32224 United States Details
University of Kansas Medical Center Research Institute Kansas City Kansas 66160 United States Details
Mayo Clinic Rochester Rochester Minnesota 55905 United States Details
Inova Schar Cancer Institute Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field